Related Experiment Video

Updated: Sep 14, 2026

Experimental Human Pneumococcal Carriage
07:47

Experimental Human Pneumococcal Carriage

Published on: February 15, 2013

Safety and immunogenicity of a heptavalent pneumococcal conjugate vaccine in infants

Kenneth M Zangwill1, David P Greenberg, Chung-Yin Chiu

  • 1UCLA Center for Vaccine Research, Harbor-UCLA Medical Center, Liu Research Building, 1124 W. Carson Street, Torrance, CA 90502, USA. kzangwill@rei.edu

Vaccine
|April 23, 2003
PubMed

Insights

This study found the heptavalent Streptococcus pneumoniae conjugate vaccine (PCV-OMPC) to be safe for infants. However, immune responses varied by serotype, and co-administration with certain Haemophilus influenzae type b (Hib) vaccines may affect immunogenicity.

Area of Science:

  • Immunology
  • Vaccinology
  • Pediatrics

Background:

  • Pneumococcal conjugate vaccines (PCV) are crucial for preventing invasive pneumococcal disease in infants.
  • Evaluating the safety and immunogenicity of different vaccine lots and combinations is essential for optimizing vaccination strategies.

Purpose of the Study:

  • To assess the safety and immunogenicity of two lots of a heptavalent Streptococcus pneumoniae conjugate vaccine (PCV-OMPC) in infants.
  • To compare the immune responses elicited by PCV-OMPC when co-administered with different Haemophilus influenzae type b (Hib) conjugate vaccines.

Main Methods:

  • A randomized trial involving 240 infants assigned to receive PCV-OMPC concurrently with either a CRM(197)-based Hib vaccine or an OMPC-based Hib-hepatitis b vaccine.
  • Infants received vaccinations at 2, 4, 6, and 12 months of age.
  • Serotype-specific antibody concentrations and seroconversion rates were measured.

Main Results:

  • Both PCV-OMPC lots were well-tolerated with no vaccine-related serious adverse events.
  • Antibody geometric mean concentrations (GMC) varied by serotype, with lower responses for serotypes 6B and 23F after the primary series.
  • Co-administration with the OMPC-based Hib vaccine (Group 2) resulted in significantly lower antibody responses for certain serotypes compared to the CRM(197)-based Hib vaccine (Group 1).

Conclusions:

  • The heptavalent Streptococcus pneumoniae conjugate vaccine (PCV-OMPC) is safe for infant immunization.
  • Immune responses to PCV-OMPC are serotype-dependent.
  • Concomitant administration of PCV-OMPC with a Hib vaccine using a homologous carrier (OMPC) may potentially reduce its immunogenicity.
Abstract

More Related Videos

Homogeneous Glycoconjugate Produced by Combined Unnatural Amino Acid Incorporation and Click-Chemistry for Vaccine Purposes13:53

Homogeneous Glycoconjugate Produced by Combined Unnatural Amino Acid Incorporation and Click-Chemistry for Vaccine Purposes

Published on: December 19, 2020

Opsono-Adherence Assay to Evaluate Functional Antibodies in Vaccine Development Against Bacillus anthracis and Other Encapsulated Pathogens13:47

Opsono-Adherence Assay to Evaluate Functional Antibodies in Vaccine Development Against Bacillus anthracis and Other Encapsulated Pathogens

Published on: May 19, 2020

Related Concept Videos

Vaccinations01:51

Vaccinations

Overview
Development of Immunocompetence01:22

Development of Immunocompetence

The initiation of cell-mediated immunity can be observed as early as the third month of fetal growth, with active antibody-mediated immunity following approximately one month later.
The initial cells that migrate from the fetal thymus settle within the skin and epithelial tissues lining the mouth, digestive tract, and in females, the uterus and vagina. These cells, including skin-based dendritic cells, serve as antigen-presenting cells, playing a key role in T cell activation.
Subsequent T...
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
Vaccines01:21

Vaccines

Vaccines are among the most effective tools in preventive medicine, designed to prepare the immune system to recognize and combat infectious agents. By introducing antigens—substances that the immune system identifies as foreign—vaccines stimulate an adaptive immune response that leads to immunological memory. This immunological memory enables the body to mount a faster and more effective response upon future exposures to the actual pathogen.Vaccines can be categorized based on the type of...
Poliomyelitis01:17

Poliomyelitis

Poliomyelitis is caused by poliovirus, a small, non-enveloped, positive-sense RNA virus of the Picornaviridae family and Enterovirus genus. Transmission occurs primarily via the fecal-oral route, often through ingestion of contaminated water or food. The virus initially replicates in the oropharynx and intestinal mucosa, particularly in lymphoid tissues such as the tonsils, Peyer’s patches, and regional lymph nodes. Primary viremia follows, allowing dissemination throughout the body.In most...
Respiratory Syncytial Virus Disease01:29

Respiratory Syncytial Virus Disease

Human respiratory syncytial virus (RSV) is a widespread pathogen that primarily targets infants and young children but also poses a serious health risk to elderly and immunocompromised individuals. Belonging to the Pneumoviridae family, RSV is a negative-sense, single-stranded RNA virus within the Pneumovirus genus. Its global health burden is significant, with millions of cases annually resulting in hospitalizations and mortality, particularly in resource-limited settings. Although most...